Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Dimitra Karagkouni, Maria J. J. Fernandez Turizo, Nikolaos Kalavros, Sean M McCabe, Alexandra W Lenart, Shivani Nanda, Athanasios Ploumakis, Antonella Amaral, Anna B Rider, Aliyah R. Sohani, Mwanasha H. Merrill, Eric D. Jacobsen, Maria Elena Cabrera, Pablo Villegas, Ioannis S Vlachos, Salvia Jain

Blood (2024) 144 (Supplement 1): 2992.

https://doi.org/10.1182/blood-2024-211658

Published: 2024

Journal Articles

Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma

Makoto Iwasaki, Caroline MacVicar, Anna B Rider, Aliyah R. Sohani, Valentina Nardi, Josie G Ford, Kusha Chopra, Jeffrey A. Barnes, Salvia Jain

Blood (2024) 144 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2024-208061

Published: 2024

Journal Articles

Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL)

Maya D. Srinivasan, Christopher Dittus, Areej El-Jawahri, Salvia Jain, Anthony Shelton, John Mark Sloan

Blood (2024) 144 (Supplement 1): 6405.

https://doi.org/10.1182/blood-2024-205425

Published: 2024

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Josie G Ford, Sean M McCabe, Alexandra W Lenart, Mark N Sorial, Mwanasha H. Merrill, Anna B Rider, Aliyah R. Sohani, Ronald A Nemec, Kusha Chopra, Caroline MacVicar, Eric D. Jacobsen, Salvia Jain

Blood (2024) 144 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2024-204392

Published: 2024

Journal Articles

Integrated Omics to Dissect the Landscape in Chemosensitive and Refractory Extranodal Natural-Killer T-Cell Lymphoma (ENKTCL): A Global Study of the PETAL (PEripheral T-Cell Lymphoma) Consortium

Blood (2024) 144 (Supplement 1): 6207.

https://doi.org/10.1182/blood-2024-208838

Published: 2024

Journal Articles

Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation

Chandan Sanghera, Josie Ford, Ruwan Gunaratne, Kusha Chopra, Anna B Rider, Aliyah R. Sohani, Sean M McCabe, Ronald A Nemec, Yi-Bin Chen, Steven McAfee, Ephraim Hochberg, Jeffrey A. Barnes, Caroline MacVicar, Eric D. Jacobsen, Mwanasha H. Merrill, Michael S. Khodadoust, David Kurtz, Salvia Jain

Blood (2024) 144 (Supplement 1): 6202.

https://doi.org/10.1182/blood-2024-206116

Published: 2024

Journal Articles

Leveraging a Novel Machine Learning Method to Predict Outcomes in Latin American (LATAM) Patients with Newly Diagnosed T and NK Cell Lymphomas (TNKL)

Blood (2024) 144 (Supplement 1): 7515.

https://doi.org/10.1182/blood-2024-208856

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Steven Horwitz, Salvia Jain, Jacob D. Soumerai, Michael T. Tees, Robert Stuver, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 467.

https://doi.org/10.1182/blood-2024-210482

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Paolo Strati, Tatyana Feldman, Christiane Querfeld, Salvia Jain, Nathanael McCurley, Rita Bàrcia, Koby Kidder, Jelle Kylstra

Blood (2023) 142 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2023-175040

Published: 2023

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Blood (2022) 140 (Supplement 1): 1696–1697.

https://doi.org/10.1182/blood-2022-163368

Published: 2022

Journal Articles

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 2253–2255.

https://doi.org/10.1182/blood-2022-162583

Published: 2022

Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9425–9426.

https://doi.org/10.1182/blood-2022-170181

Published: 2022

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Matko Kalac, Salvia Jain, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Bryan D. Huber, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9422–9424.

https://doi.org/10.1182/blood-2022-165165

Published: 2022

Journal Articles

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Blood (2022) 139 (13): 2024–2037.

https://doi.org/10.1182/blood.2021014701

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Nazila Shafagati, Robert N. Stuver, Leora Boussi, Min Jung Koh, Allison Park, Paul Bain, Francine M. Foss, Changyu Shen, Salvia Jain

Blood (2021) 138 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2021-150315

Published: 2021

NARROW

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma

Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL)

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Integrated Omics to Dissect the Landscape in Chemosensitive and Refractory Extranodal Natural-Killer T-Cell Lymphoma (ENKTCL): A Global Study of the PETAL (PEripheral T-Cell Lymphoma) Consortium

Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation

Leveraging a Novel Machine Learning Method to Predict Outcomes in Latin American (LATAM) Patients with Newly Diagnosed T and NK Cell Lymphomas (TNKL)

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only